Therefore, in the present study we utilized the rhGNS without a myc tag to treat MPS IIID mice with a proof of efficacy repeat dosing regimen and a clinically applicable treatment regimen. The gene discussed is MYC; the disease is mucopolysaccharidosis type 3D.